BackRecursion Pharmaceuticals Overview
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Target Price

Analysts' average 12-month price target for Recursion Pharmaceuticals is $5.6.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.52

Average Target Price

$5.6059.1% upside

2 analysts in the last 4 months

High: $5.9 | Low: $5.3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-16Morgan StanleySean Laaman$5.967.6% upsideOpen
2026-08-17Morgan Stanley$5.350.6% upsideOpen
2026-05-14Morgan Stanley$5.556.3% upsideOpen
2025-12-17UBS$11212.5% upsideOpen
2025-12-17Morgan Stanley$11212.5% upsideOpen
2025-02-28Leerink Partners$670.5% upsideOpen
2024-09-04NeedhamGil Blum$11212.5% upsideOpen
2024-09-03KeyBancScott Schoenhaus$12240.9% upsideOpen
2024-09-03JefferiesDennis Ding$670.5% upsideOpen
2024-06-26KeyBancScott Schoenhaus$16354.5% upsideOpen

Recursion Pharmaceuticals (RXRX) FAQ

Recursion Pharmaceuticals's target price stands at $5.6. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $5.6 for RXRX implies 59.1% upside versus today's price ($3.52). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Recursion Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places RXRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Recursion Pharmaceuticals's reading of $5.6 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.